arrow
A

Anna van Rhenen

University Medical Center Utrecht
H指数:17
被引数:1,729

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Incidence and characteristics of cytokine release syndrome in patients with systemic sclerosis undergoing autologous haematopoietic stem cell transplantation

系统性硬化症患者自体造血干细胞移植中细胞因子释放综合征的发生率及特征

2026-10-110
OAAI
Peri-transplant ruxolitinib in myelofibrosis patients undergoing αβTCR and CD19-depleted stem cell transplantation

移植前后使用鲁索利替尼治疗接受αβTCR和CD19耗竭干细胞移植的骨髓纤维化患者

2026-10-060
PRE
Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed/refractory acute myeloid leukemia
2026-03-011
PRE
αβT/CD19-depleted Allogeneic Stem Cell Transplantation in Adults with Inborn Errors of Immunity

αβT/CD19耗竭的异基因造血干细胞移植在免疫先天性缺陷成人中的应用

2026-02-030
OAAI
Clinicians’ experiences, perspectives, barriers, and facilitators of integrating palliative care into hematological malignancy care: a qualitative interview study

临床医生在将姑息治疗整合到血液学肿瘤护理中的经验、观点、障碍和促进因素:一项定性访谈研究

2025-07-180
PRE
Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis: Results from an international questionnaire-based study

系统性硬化症自体造血干细胞移植后疾病进展的管理:一项基于国际问卷调查的结果

2025-04-010
OAAI
Improved GVHD-free and relapse-free survival after ex vivo αβTCR and CD19 depleted allogeneic HSCT compared to T cell replete HSCT

与含T细胞的异基因HSCT相比,经体外αβTCR和CD19清除的异基因HSCT改善了无GVHD和无复发生存率。

2025-03-150
PRE
Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane

HOVON 170 DLBCL-预期试验的原理和设计: 用右雷佐生预防蒽环类药物诱导的心功能障碍

2025-01-280
OAAI
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome
2024-10-050
OAAI
The association between hospital volume and overall survival in adult AML patients treated with intensive chemotherapy

医院收治量与接受强化疗的成年AML患者总生存期之间的关联

2024-09-010
PRE